These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 17409807)

  • 21. [Biology of small-cell bronchogenic carcinoma: recent advances].
    Levy R; Andrieu JM; Even P
    Bull Cancer; 1992; 79(1):25-46. PubMed ID: 1325850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetic and molecular aspects of lung cancer.
    Panani AD; Roussos C
    Cancer Lett; 2006 Jul; 239(1):1-9. PubMed ID: 16112428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
    Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
    Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant DNA methylation in lung cancer: biological and clinical implications.
    Zöchbauer-Müller S; Minna JD; Gazdar AF
    Oncologist; 2002; 7(5):451-7. PubMed ID: 12401908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
    Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
    Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
    Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
    Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lung cancer in women: clinical features and factors related to survival].
    Sen E; Kaya A; Erol S; Savas I; Gonullu U
    Tuberk Toraks; 2008; 56(3):266-74. PubMed ID: 18932027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.
    Osada H; Takahashi T
    Oncogene; 2002 Oct; 21(48):7421-34. PubMed ID: 12379883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma.
    Konno S; Morishita Y; Fukasawa M; Shu Y; Wang D; Tanaka R; Minami Y; Iijima T; Noguchi M
    Cancer; 2004 Dec; 102(6):348-54. PubMed ID: 15481085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease.
    Behrens C; Travis LB; Wistuba II; Davis S; Maitra A; Clarke EA; Lynch CF; Glimelius B; Wiklund T; Tarone R; Gazdar AF
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1027-35. PubMed ID: 11045784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular genetic abnormalities in the pathogenesis of human lung cancer.
    Forgacs E; Zöchbauer-Müller S; Oláh E; Minna JD
    Pathol Oncol Res; 2001; 7(1):6-13. PubMed ID: 11349214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in understanding the molecular pathogenesis of human lung cancer.
    Sekido Y; Fong KM; Minna JD
    Biochim Biophys Acta; 1998 Aug; 1378(1):F21-59. PubMed ID: 9739759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
    Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
    Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers.
    Destro A; Bianchi P; Alloisio M; Laghi L; Di Gioia S; Malesci A; Cariboni U; Gribaudi G; Bulfamante G; Marchetti A; Bosari S; Infante M; Ravasi G; Roncalli M
    Lung Cancer; 2004 Apr; 44(1):23-32. PubMed ID: 15013580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pathogenesis of lung cancer.
    Fong KM; Sekido Y; Minna JD
    J Thorac Cardiovasc Surg; 1999 Dec; 118(6):1136-52. PubMed ID: 10595998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
    Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
    Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
    Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
    Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biologic features of non-small cell lung cancer. Clinical implications.
    Rusch VW; Dmitrovsky E
    Chest Surg Clin N Am; 1995 Feb; 5(1):39-55. PubMed ID: 7743147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
    Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.